Literature DB >> 12745133

Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa.

Marieke J van der Werf1, Sake J de Vlas, Simon Brooker, Caspar W N Looman, Nico J D Nagelkerke, J Dik F Habbema, Dirk Engels.   

Abstract

Health policy making in developing countries requires estimates of the (global) burden of disease. At present, most of the available data on schistosomiasis is limited to numbers of individuals harbouring the infection. We explored the relationship between the presence of schistosome infection and clinical morbidity, in order to estimate numbers of individuals with disease-specific morbidity for Schistosoma haematobium and Schistosoma mansoni infection in sub-Saharan Africa. We searched the literature for cross-sectional data from field studies reporting both schistosome infection and morbidity. This was used to derive a functional relationship between morbidity and infection. After standardisation for diagnostic method, the number of individuals with specific types of clinical morbidity or pathology was predicted. As only aggregated prevalences of infection were available for countries or areas, we adjusted for heterogeneity in infection levels within communities in those countries. In total, 70 million individuals out of 682 million (2000 estimate) in sub-Saharan Africa were estimated to experience haematuria in the last 2 weeks associated with S. haematobium infection, and 32 million dysuria. Ultrasound detected serious consequences of S. haematobium, major bladder wall pathology and major hydronephrosis, were predicted at 18 and 10 million, respectively. Infection with S. mansoni was estimated to cause diarrhoea in 0.78 million individuals, blood in stool in 4.4 million and hepatomegaly in 8.5 million. As the associations between prevalence of S. mansoni infection and prevalence of diarrhoea and blood in stool were not very clear, the resulting estimates may be underestimations. Using the very limited data available, we estimated the mortality rates due to non-functioning kidney (from S. haematobium) and haematemesis (from S. mansoni) at 150000 and 130000 per year. Given the overall high number of cases with schistosomiasis-related disease and associated death, we conclude that schistosomiasis remains an important public health problem in sub-Saharan Africa.

Entities:  

Mesh:

Year:  2003        PMID: 12745133     DOI: 10.1016/s0001-706x(03)00029-9

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  372 in total

1.  Impact of drought on the spatial pattern of transmission of Schistosoma haematobium in coastal Kenya.

Authors:  Francis M Mutuku; Charles H King; Amaya L Bustinduy; Peter L Mungai; Eric M Muchiri; Uriel Kitron
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Molecular cloning and characterization of a HSP70 gene from Schistosoma japonicum.

Authors:  Jie Yang; Linlin Yang; Zhiyue Lv; Juan Wang; Qixian Zhang; Huanqin Zheng; Zhongdao Wu
Journal:  Parasitol Res       Date:  2011-11-11       Impact factor: 2.289

Review 3.  Helminthic infections.

Authors:  Shally Awasthi; D A P Bundy; Lorenzo Savioli
Journal:  BMJ       Date:  2003-08-23

4.  A pilot study on cytotoxic T lymphocyte-4 gene polymorphisms in urinary schistosomiasis.

Authors:  Zulkarnain Md Idris; Maria Yazdanbakhsh; Ayola Akim Adegnika; Bertrand Lell; Saadou Issifou; Rahmah Noordin
Journal:  Genet Test Mol Biomarkers       Date:  2012-01-30

5.  Schistosomiasis and Infertility in East Africa.

Authors:  Patricia A Woodall; Michael R Kramer
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

6.  In vitro efficacy of the essential oil of Piper cubeba L. (Piperaceae) against Schistosoma mansoni.

Authors:  Lizandra G Magalhães; Julia M de Souza; Kamila A L Wakabayashi; Rosangela da S Laurentiz; Adriana H C Vinhólis; Karen C S Rezende; Guilherme V Simaro; Jairo K Bastos; Vanderlei Rodrigues; Viviane R Esperandim; Daniele S Ferreira; Antônio E M Crotti; Wilson R Cunha; Márcio L A e Silva
Journal:  Parasitol Res       Date:  2011-10-19       Impact factor: 2.289

7.  Cloning and characterization of an orphan seven transmembrane receptor from Schistosoma mansoni.

Authors:  M S Pearson; D P McManus; D J Smyth; M K Jones; A M Sykes; A Loukas
Journal:  Parasitology       Date:  2007-08-23       Impact factor: 3.234

8.  Pharmacokinetics of the Antischistosomal Lead Ozonide OZ418 in Uninfected Mice Determined by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Anna Leonidova; Mireille Vargas; Jörg Huwyler; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase.

Authors:  Wendy A Lea; Ajit Jadhav; Ganesha Rai; Ahmed A Sayed; Cynthia L Cass; James Inglese; David L Williams; Christopher P Austin; Anton Simeonov
Journal:  Assay Drug Dev Technol       Date:  2008-08       Impact factor: 1.738

10.  Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa.

Authors:  Martial L Ndeffo Mbah; Eyrun F Kjetland; Katherine E Atkins; Eric M Poolman; Evan W Orenstein; Lauren Ancel Meyers; Jeffrey P Townsend; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.